We are also looking at where we can expand use of the devices to help treat other conditions. Q: What’s the future for Speedboat Inject? Do you see it being used for other conditions?Ī: The device has proved highly effective in treating colon cancers and as more and more clinicians are trained and become proficient in using it, I expect the number of patients who have access to the treatment to grow. We estimate that our SSD procedure with Speedboat Inject can save the NHS over £10,000 per procedure versus a traditional surgical outcome, which is approximately a 50% saving. The result is that not only are recovery times drastically reduced but scarce hospital resources are freed up which is even more important given the delays to elective procedures that have arisen due to Covid-19. Patients can be out of hospital within a few hours of the treatment and at worst will only need an overnight stay. Using Speedboat Inject and the SSD procedure means that only local anaesthetic is needed. In some instances, if there were complications, patients may need the colostomy bag for life, which is totally life changing. They would be looking at a week-long stay in hospital and some would have needed a colostomy bag for up to six months afterwards. The procedure known as Speedboat Submucosal Dissection (SSD), is undertaken using an endoscope, and allows clinicians to pinpoint, excise and remove cancerous and pre-cancerous lesions from the colon.īefore the introduction of our device, patients would typically have undergone open surgery or laparoscopic surgery to remove such growths. Using bipolar radio frequency and super high-frequency microwave energy it can dissect, resect, coagulate and inject, all in a single device. What has the new technology meant for patients and the NHS?Ī: Speedboat Inject was our first product, designed for use in the gastrointestinal tract. Q: Your Speedboat Inject device was developed to treat early-stage colon cancers and has been used to treat countless patients worldwide. Almost 20 years after the company was formed, founder Professor Chris Hancock tells us about the pioneering technology, the role of IP of in the company’s success and how the Covid-19 pandemic drove creativity across the organisation. Creo Medical’s cutting-edge medical devices have several applications, including the treatment of cancers at an early stage, with minimally-invasive techniques that cut recovery times for patients and free up valuable NHS resources.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |